Prostate Cancer Clinical Trials
Prostate Cancer clinical trials evaluate new drugs, immunotherapies, radiation approaches, and combination treatments for prostate Cancer. Corterve aggregates actively recruiting Prostate Cancer studies from the public ClinicalTrials.gov registry so you can browse them by location and eligibility. Many oncology trials enroll patients at different stages of disease, including newly diagnosed and previously treated. This is general information, not medical advice — review any study with your oncology care team before enrolling.
Recruiting Prostate Cancer studies
- Precision-Based Genomics in Prostate CancerNCT04706663National Cancer Institute (NCI)Prostate CancerLa Jolla, California
- A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate CancerNCT05800665PHASE1Genentech, Inc.Advanced Prostate CancerScottsdale, Arizona
- Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine CellsNCT05691465PHASE2National Cancer Institute (NCI)Metastatic Prostate Adenocarcinoma With Neuroendocrine DifferentiationDuarte, California
- FOG-001 in Locally Advanced or Metastatic Solid TumorsNCT05919264PHASE1, PHASE2Parabilis Medicines, Inc.CancerPhoenix, Arizona
- FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY TrialNCT06244004PHASE2Northwestern UniversityCastration-Sensitive Prostate CarcinomaChicago, Illinois
- A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)NCT07488923PHASE1Moonlight Bio, IncSmall Cell Lung Cancer (SCLC )St Louis, Missouri
- A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)NCT06136650PHASE3Merck Sharp & Dohme LLCMetastatic Castration-resistant Prostate Cancer (mCRPC)Tucson, Arizona
- A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate CancerNCT07287150PHASE2Hoffmann-La RocheMetastatic Castration-Resistant Prostate CancerLos Angeles, California
- Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)NCT06136624PHASE3Merck Sharp & Dohme LLCProstate Cancer MetastaticOrange, California
- A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate CancerNCT07567846PHASE1, PHASE2Genentech, Inc.Advanced Prostate CancerScottsdale, Arizona
- IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation TherapyNCT07686380PHASE2National Cancer Institute (NCI)Recurrent Prostate CancerBethesda, Maryland
- Study of Oral MRT-2359 With Apalutamide in Prostate CancerNCT07745361PHASE2Monte Rosa Therapeutics, IncCastration-Resistant Prostate Cancer (CRPC)Los Angeles, California
Prostate Cancer trials by state
Prostate Cancer trials by metro
Frequently asked questions
- How do I find recruiting Prostate Cancer clinical trials?
- Browse the actively recruiting Prostate Cancer studies listed on this page, or take an assessment to see trials you may qualify for based on your profile.
- Are Prostate Cancer clinical trials free to join?
- Costs, travel support, and any payment for taking part vary by study. Ask the study team what is covered before you decide to join.
- Who can take part in a Prostate Cancer clinical trial?
- Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.